title: EFNS task force--therapy of nystagmus and oscillopsia.
abstract: An overview of possible treatment options for oculomotor disorders that prevent clear vision is given. Downbeat nystagmus, upbeat nystagmus, seesaw nystagmus, periodic alternating nystagmus, acquired pendular nystagmus, and saccadic oscillations such as opsoclonus/ocular flutter are discussed. In addition, superior oblique myokymia and vestibular paroxysmia are reviewed. All treatment recommendations available in the literature are classified as class C only. In general, only some of the patients benefit from the treatment.
authors.affiliation: Department of Neurology, University of Munich, Munich, Germany. astraube@brain.nefo.med.uni-muenchen.de
authors.forename: A
authors.initials: A
authors.lastname: Straube
authors.forename: R J
authors.initials: RJ
authors.lastname: Leigh
authors.forename: A
authors.initials: A
authors.lastname: Bronstein
authors.forename: W
authors.initials: W
authors.lastname: Heide
authors.forename: P
authors.initials: P
authors.lastname: Riordan-Eva
authors.forename: C C
authors.initials: CC
authors.lastname: Tijssen
authors.forename: I
authors.initials: I
authors.lastname: Dehaene
authors.forename: D
authors.initials: D
authors.lastname: Straumann
mesh_terms: D026683:Advisory Committees; D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use; D005060:Europe; D018755:GABA Agonists / Q000627:therapeutic use; D006801:Humans; D009759:Nystagmus, Pathologic / Q000188:drug therapy* / Q000503:physiopathology; D015840:Oculomotor Nerve Diseases / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D000927:Anticonvulsants; D018755:GABA Agonists